Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Mustang Bio Inc (MBIO)

Mustang Bio Inc (MBIO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 70,926
  • Shares Outstanding, K 100,291
  • Annual Sales, $ 0 K
  • Annual Income, $ -66,370 K
  • 60-Month Beta 1.77
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.74
Trade MBIO with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.77
  • Most Recent Earnings -0.20 on 05/12/22
  • Next Earnings Date 05/13/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 738.64% ( +7.82%)
  • Historical Volatility 78.51%
  • IV Percentile 100%
  • IV Rank 100.00%
  • IV High 738.64% on 05/20/22
  • IV Low 41.25% on 02/16/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 8
  • Volume Avg (30-Day) 40
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 10,117
  • Open Int (30-Day) 9,806

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.21
  • Number of Estimates 3
  • High Estimate -0.20
  • Low Estimate -0.21
  • Prior Year -0.16
  • Growth Rate Est. (year over year) -31.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6201 +14.05%
on 05/12/22
0.9195 -23.09%
on 04/21/22
-0.1673 (-19.13%)
since 04/20/22
3-Month
0.6201 +14.05%
on 05/12/22
1.1700 -39.56%
on 03/24/22
-0.1771 (-20.03%)
since 02/18/22
52-Week
0.6201 +14.05%
on 05/12/22
4.0600 -82.58%
on 06/11/21
-2.5428 (-78.24%)
since 05/20/21

Most Recent Stories

More News
Mustang Bio Announces Updated Interim Data on X-Linked Severe Combined Immunodeficiency Treatment with Lentiviral Vector Gene Therapy Support Upcoming Multicenter Pivotal Phase 2 Trial for MB-107

All 23 treated patients are alive at 2.6-year median follow-up without evidence of malignant transformation Data representing largest cohort of infants...

MBIO : 0.7072 (-1.27%)
Mustang Bio Reports First Quarter 2022 Financial Results and Recent Corporate Highlights

Data from two programs selected for oral presentations at the upcoming American Society of Gene & Cell Therapy 25th Annual Meeting and the European...

MBIO : 0.7072 (-1.27%)
Mustang Bio Announces Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy, Selected for Oral Presentation at European Hematology Association 2022 Hybrid Congress

Favorable safety profile, high overall response and complete response rates, and CAR T persistence observed in patients with relapsed or refractory...

MBIO : 0.7072 (-1.27%)
Mustang Bio Announces Data on Treatment with Lentiviral Viral Vector Gene Therapy for X-Linked Severe Combined Immunodeficiency Selected for Oral Presentation at American Society of Gene & Cell Therapy 25th Annual Meeting

Data represent largest cohort of infants with XSCID, also known as bubble boy disease, who received lentiviral gene therapy with the longest follow-up to...

MBIO : 0.7072 (-1.27%)
Mustang Bio Announces Upcoming MB-106 CD20-Targeted CAR T Data Presentations

Fred Hutch’s Dr. Mazyar Shadman to present data on Mustang’s autologous CAR T-cell therapy for the treatment of B-cell non-Hodgkin lymphomas and chronic...

MBIO : 0.7072 (-1.27%)
Mustang Bio Announces a Phase 1 Clinical Trial Combining MB-101 (IL13Rα2‐targeted CAR T cell therapy) and MB-108 (C134 oncolytic virus) for the Treatment of Glioblastoma

MB‐101 (IL13Rα2‐targeted CAR T cell therapy) and MB-108 (C134 oncolytic virus) are well tolerated in patients with recurrent GBM in ongoing Phase 1...

MBIO : 0.7072 (-1.27%)
Mustang Bio to Present at the Virtual Fortress Biotech R&D Summit Hosted by B. Riley Securities

WORCESTER, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on...

MBIO : 0.7072 (-1.27%)
Mustang Bio Reports Full-Year 2021 Financial Results and Recent Corporate Highlights

WORCESTER, Mass., March 23, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on...

MBIO : 0.7072 (-1.27%)
Mustang Bio to Participate in Three March 2022 Investor Conferences

WORCHESTER, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on...

MBIO : 0.7072 (-1.27%)
Mustang Bio Announces City of Hope MB-105 Prostate Stem Cell Antigen CAR T Data Selected for Presentation at the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium

WORCESTER, Mass., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on...

MBIO : 0.7072 (-1.27%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Mustang Bio, Inc. a subsidiary of Fortress Biotech, Inc., is a clinical'stage biopharmaceutical company. It focused on the development and commercialization of novel cancer immunotherapy products designed to leverage the patient's own immune system to eliminate cancer cells. Mustang Bio, Inc. is based...

See More

Key Turning Points

3rd Resistance Point 0.8116
2nd Resistance Point 0.7799
1st Resistance Point 0.7435
Last Price 0.7072
1st Support Level 0.6754
2nd Support Level 0.6437
3rd Support Level 0.6073

See More

52-Week High 4.0600
Fibonacci 61.8% 2.7460
Fibonacci 50% 2.3400
Fibonacci 38.2% 1.9341
Last Price 0.7072
52-Week Low 0.6201

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar